Clinical Trial Update: Phase II Study Aiming to Evaluate the Efficacy and Safety of Nilotinib Patients With Gastrointestinal Stromal Tumors (GIST) Resistant or Intolerant to Imatinib and or to 2nd Line Tyrosine Kinas (TK) Inhibitor [Phase 2]

View source ↗

Summary

This is a completed Phase II trial assessing the efficacy and safety of nilotinib in patients with gastrointestinal stromal tumors that are resistant or intoler…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Stromal Tumors

Drugs mentioned

• Nilotinib (nilotinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Gastrointestinal Stromal Tumors (GIST) | Phase 2 | Status: COMPLETED